Unicycive Therapeutics, Inc.
NASDAQ:UNCY
Overview | Financials
Company Name | Unicycive Therapeutics, Inc. |
Symbol | UNCY |
Currency | USD |
Price | 0.435 |
Market Cap | 41,016,640 |
Dividend Yield | 0% |
52-week-range | 0.202 - 1.818 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Dr. Shalabh K. Gupta M.D., MPA |
Website | https://www.unicycive.com |
An error occurred while fetching data.
About Unicycive Therapeutics, Inc.
Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD